Validating HepatoPredict for liver cancer surgery outcome
Part of Cancer, Digestive system clinical trials.
This study looks at how well the HepatoPredict tool predicts outcomes for people with liver cancer who had a liver transplant or surgery to remove the tumor. The researchers are checking if the tool was accurate by reviewing data from at least 5 years after the procedure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You had liver cancer (HCC) and either a liver transplant or surgery to remove the tumor.
- It has been at least 5 years since your transplant or surgery.
- You did not have cancer spread outside the liver when you were first diagnosed.
- If you are still alive, you must have signed a consent form to allow your information to be used.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a blood test (looking at sugars in the blood) to help predict whether liver cancer will come back after a liver transplant. It may help doctors monitor you more accurately and earlier if cancer returns.
This study looks at two blood markers (AFP and PIVKA-II) to see if they can help predict outcomes for people getting a liver transplant for liver cancer. It aims to find better ways to guide care after transplant.
This study uses an AI tool to predict how liver cancer might come back after surgery. It is for people with early-stage liver cancer who are already scheduled for surgery and have recent MRI scans.
This study uses non-invasive tests, like scans or blood tests, to predict how well people with liver cancer (hepatocellular carcinoma, or HCC) will do after curative treatment. It may help doctors better understand your condition without needing invasive procedures.
This study looks at a prediction tool that estimates outcomes for people with liver cancer and cirrhosis, to help decide whether a liver transplant is a good option. It may help doctors choose the right timing and patients who could benefit most from transplantation.
This study examines medical records from patients who received a liver transplant for hepatocellular carcinoma (a type of liver cancer) between 2018 and 2023. The goal is to understand treatment outcomes and improve care for future patients.
Hear when a new Hepato Cellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.